Brief: Noxopharm Announces New Proprietary Product Candidate Based On MRNA Technology
28/03/2023 02:14
March 28 (Reuters) - Noxopharm Ltd NOX.AX :
* ANNOUNCES DEVELOPMENT OF NEW PROPRIETARY PRODUCT CANDIDATE
BASED
ON MRNA TECHNOLOGY AS PART OF SOFRATM PRECLINICAL PLATFORM
Source text for Eikon: ID:nASX1kkcsD
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer